152 related articles for article (PubMed ID: 27189717)
1. Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.
Huijts CM; Santegoets SJ; Quiles Del Rey M; de Haas RR; Verheul HM; de Gruijl TD; van der Vliet HJ
Clin Immunol; 2016 Jul; 168():47-54. PubMed ID: 27189717
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
3. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
Kirstein MM; Boukouris AE; Pothiraju D; Buitrago-Molina LE; Marhenke S; Schütt J; Orlik J; Kühnel F; Hegermann J; Manns MP; Vogel A
Liver Int; 2013 May; 33(5):780-93. PubMed ID: 23489999
[TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
5. Targeting of PI3K/AKT/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development.
Herrero-Sánchez MC; Rodríguez-Serrano C; Almeida J; San Segundo L; Inogés S; Santos-Briz Á; García-Briñón J; Corchete LA; San Miguel JF; Del Cañizo C; Blanco B
J Hematol Oncol; 2016 Oct; 9(1):113. PubMed ID: 27765055
[TBL] [Abstract][Full Text] [Related]
6. Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma.
Rosich L; Montraveta A; Xargay-Torrent S; López-Guerra M; Roldán J; Aymerich M; Salaverria I; Beà S; Campo E; Pérez-Galán P; Roué G; Colomer D
Oncotarget; 2014 Aug; 5(16):6788-800. PubMed ID: 25216518
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Badura S; Tesanovic T; Pfeifer H; Wystub S; Nijmeijer BA; Liebermann M; Falkenburg JH; Ruthardt M; Ottmann OG
PLoS One; 2013; 8(11):e80070. PubMed ID: 24244612
[TBL] [Abstract][Full Text] [Related]
8. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
9. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.
Kuger S; Flentje M; Djuzenova CS
Radiat Oncol; 2015 Oct; 10():214. PubMed ID: 26498922
[TBL] [Abstract][Full Text] [Related]
11. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
[TBL] [Abstract][Full Text] [Related]
13. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
14. Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors.
Chanal M; Chevallier P; Raverot V; Fonteneau G; Lucia K; Monteserin Garcia JL; Rachwan A; Jouanneau E; Trouillas J; Honnorat J; Auger C; Theodoropoulou M; Raverot G
Mol Cancer Ther; 2016 Jun; 15(6):1261-70. PubMed ID: 26983879
[TBL] [Abstract][Full Text] [Related]
15. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
Kim A; Lee JE; Lee SS; Kim C; Lee SJ; Jang WS; Park S
Int J Cancer; 2013 Aug; 133(4):984-96. PubMed ID: 23475782
[TBL] [Abstract][Full Text] [Related]
16. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
[TBL] [Abstract][Full Text] [Related]
17. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
Mueller A; Bachmann E; Linnig M; Khillimberger K; Schimanski CC; Galle PR; Moehler M
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1601-15. PubMed ID: 22543857
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of DNA methyltransferase as a novel therapeutic strategy to overcome acquired resistance to dual PI3K/mTOR inhibitors.
Qian XJ; Li YT; Yu Y; Yang F; Deng R; Ji J; Jiao L; Li X; Wu RY; Chen WD; Feng GK; Zhu XF
Oncotarget; 2015 Mar; 6(7):5134-46. PubMed ID: 25762617
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PI3K-Akt-mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth.
Wei S; Han C; He F; Song Q; Kang B; Liu H; Li L; Xu H; Zeng X
J Anim Physiol Anim Nutr (Berl); 2017 Oct; 101(5):e133-e143. PubMed ID: 27859698
[TBL] [Abstract][Full Text] [Related]
20. Vertical inhibition of PI3K/Akt/mTOR signaling demonstrates in vitro and in vivo anti-fibrotic activity.
Liang M; Lv J; Chu H; Wang J; Chen X; Zhu X; Xue Y; Guan M; Zou H
J Dermatol Sci; 2014 Nov; 76(2):104-11. PubMed ID: 25258031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
